MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
ACET - Adicet Bio Inc
$13.93
-0.77(-5.24%)9:00:00 PM 1/26/2021
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors or T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Its products pipeline includes ADI-001, which is in Phase 1 clinical study to treat non-Hodgkin's lymphoma; and ADI-002 that is in Phase 1 clinical study for the treatment of hepatocellular carcinoma and other solid tumors. The company is based in Menlo Park, California.
Stock Chart

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
Peers

Stock news

    01/7/2021ACET
    Adicet Bio to Participate in Upcoming Investor Conferences

    MENLO PARK, Calif. and BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two virtual investor conferences in January. Details of the events are as follows:H.C. Wainwright Bioconnect 2021 Conference The presentation will be available for on-demand viewing starting January 11, ...

    12/16/2020ACET
    We're Hopeful That Adicet Bio (NASDAQ:ACET) Will Use Its Cash Wisely

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

    12/8/2020ACET
    Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit

    MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer and Stewart Abbot, Ph.D., Chief Scientific and Operating Officer, will participate in a fireside chat at The JMP Securities Hematology Summit on Tuesday, December 15, 2020 at 2:00 PM ET. A live audio webc...

    12/8/2020ACET
    Is ACET A Good Stock To Buy Now?

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

    12/1/2020ACET
    Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors

    MENLO PARK, Calif. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Bastiano Sanna, Ph.D., to its Board of Directors. Dr. Sanna brings significant expertise in advancing research, development and manufacturing of cell therapies. He currently serves as Executive Vice President and Chief of Cell and...

    11/5/2020ACET
    Adicet Reports Third Quarter 2020 Financial Results and Provides Business Update

    MENLO PARK, Calif. and BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results for the third quarter ended September 30, 2020. “We are extremely proud of the milestones we’ve achieved this quarter, including the completion of the merger between Adicet Bio and resTORbio, the clearance of our IND application fo...

    10/26/2020ACET
    Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer

    MENLO PARK, Calif. and BOSTON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Don Healey, Ph.D., as Chief Technology Officer. Dr. Healey will lead the development of Adicet’s genetically-modified T cell therapies for clinical development and commercialization, including manufacturing, viral vector operation...

    10/22/2020ACET
    Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy

    Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin’s lymphomaMENLO PARK, Calif. and BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-001, an allogeneic gamma de...